Equities

Diamyd Medical AB

Diamyd Medical AB

Actions
  • Price (SEK)11.70
  • Today's Change0.82 / 7.54%
  • Shares traded146.23k
  • 1 Year change-20.00%
  • Beta1.8321
Data delayed at least 15 minutes, as of May 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

  • Revenue in SEK (TTM)282.00k
  • Net income in SEK-120.18m
  • Incorporated1984
  • Employees26.00
  • Location
    Diamyd Medical ABKungsgatan 29STOCKHOLM 111 56SwedenSWE
  • Phone+46 86610026
  • Fax+46 86616368
  • Websitehttps://www.diamyd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cantargia AB0.00-280.03m656.13m22.00--3.89-----1.65-1.650.000.91860.00----0.00-80.18-55.08-100.27-61.35------------0.00------24.69------
Orexo AB638.60m-128.40m668.53m116.00--11.26--1.05-3.73-3.7318.551.710.67381.522.885,505,173.00-13.55-6.41-20.60-9.9986.0986.76-20.11-11.831.580.36040.8894--2.32-3.9927.76--25.77--
IRLAB Therapeutics AB5.68m-157.30m675.84m28.00--8.82--119.03-3.03-3.030.10951.480.0274--0.4652218,384.60-75.97-27.12-94.23-30.42-1,952.47-72.18-2,770.38-155.57----0.2646---90.71216.07-56.82---22.56--
Oncopeptides AB35.22m-249.11m704.83m57.00--7.47--20.01-1.96-1.960.27760.44740.1129--1.44617,894.80-79.88-141.28-101.04-200.49103.06---707.30-2,689.06----0.7065--321.54--26.29------
Nightingale Health Oyj42.67m-210.86m820.01m81.00--1.20--19.22-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Intellego Technologies AB186.49m59.60m843.28m62.0013.735.5813.364.522.332.337.355.740.88413.873.693,007,968.0028.26--44.00--68.73--31.96--2.075.820.1684--222.74--493.56------
Moberg Pharma AB (publ)0.00-21.09m894.83m----1.44-----1.20-1.200.0021.840.00-------3.52---3.66----------3.04--0.0077---100.00---34.26------
BioPorto A/S48.46m-88.16m967.46m31.00--10.27--19.97-0.1605-0.16050.08830.15850.3123.4011.96998,645.20-56.77-71.10-79.27-96.5565.1963.38-181.95-239.223.09-1,718.970.1076--6.873.5425.81---51.56--
Vistin Pharma ASA438.31m56.23m1.05bn77.0018.613.5214.132.391.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Diamyd Medical AB282.00k-120.18m1.05bn26.00--5.70--3,735.74-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
XSpray Pharma AB (publ)0.00-179.67m1.07bn26.00--1.92-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Cereno Scientific AB0.00-48.11m1.10bn5.00--4.21-----0.241-0.2410.000.92580.00----0.00-19.22-16.81-20.75-18.26-----------12.920.1734-------73.95--44.79--
Infant Bacterial Therapeutics AB0.00-123.07m1.21bn8.00--4.11-----9.90-9.900.0022.650.00----0.00-35.11-16.11-38.65-16.69------------0.00-------88.03------
SyntheticMR AB (publ)89.21m10.01m1.21bn37.00119.0210.4074.6313.600.24450.24452.172.800.6599--1.612,411,162.007.417.198.898.85105.78106.7411.229.08--14.130.010721.5030.6713.0570.34-7.3326.79--
Arcticzymes Technologies ASA118.93m18.72m1.22bn61.0064.573.9448.4310.220.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Data as of May 13 2024. Currency figures normalised to Diamyd Medical AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.03%Per cent of shares held by top holders
HolderShares% Held
Evli Fund Management Co. Ltd.as of 30 Apr 202430.00k0.03%
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.